Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Euro Surveill. 2024 Oct;29(40). doi: 10.2807/1560-7917.ES.2024.29.40.2400618.
During 2023/24, all children aged 6 to 59 months were targeted for seasonal influenza vaccination in Spain nationally. Using a test-negative case-control design with sentinel surveillance data, we estimated adjusted influenza vaccine effectiveness (IVE) against any influenza type to be 70% (95% confidence interval (CI): 51 to 81%) for primary care patients with acute respiratory illness (ARI) and 77% (95% CI: 21 to 93%) for hospitalised patients with severe ARI. In primary care, where most subtyped viruses (61%; 145/237) were A(H1N1), adjusted IVE was 77% (95% CI: 56 to 88%) against A(H1N1)pdm09.
2023/24 年度,西班牙全国所有 6 至 59 月龄儿童均作为目标人群接种季节性流感疫苗。我们采用带有哨点监测数据的病例对照测试阴性设计,针对急性呼吸道疾病(ARI)的初级保健患者,估计针对任何流感类型的流感疫苗调整后有效性(IVE)为 70%(95%置信区间(CI):51%至 81%),对患有严重 ARI 的住院患者为 77%(95%CI:21%至 93%)。在初级保健中,大多数(61%;145/237)亚型病毒为 A(H1N1),针对 A(H1N1)pdm09 的调整后 IVE 为 77%(95%CI:56%至 88%)。